Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BNTCNASDAQ:OLMANASDAQ:SNTINASDAQ:TRDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTCBenitec Biopharma$16.00+2.5%$13.51$5.74▼$16.90$409.60M0.3441,029 shs17,642 shsOLMAOlema Pharmaceuticals$4.34-0.9%$4.46$2.86▼$16.62$296.95M2.03857,225 shs996,722 shsSNTISenti Biosciences$3.09$3.38$1.52▼$16.94$80.59M2.31799,645 shs9,934 shsTRDAEntrada Therapeutics$8.27+1.6%$8.32$7.10▼$21.79$313.87M0.04132,285 shs50,928 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTCBenitec Biopharma+3.58%+18.35%+3.72%+30.41%+104.05%OLMAOlema Pharmaceuticals-17.67%-13.10%-22.06%+4.29%-54.75%SNTISenti Biosciences+0.98%-3.44%-6.93%+7.29%+3.00%TRDAEntrada Therapeutics+6.27%+8.53%-11.81%-25.93%-47.38%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBNTCBenitec Biopharma2.343 of 5 stars3.62.00.00.02.72.50.0OLMAOlema Pharmaceuticals2.3162 of 5 stars3.51.00.00.02.72.50.6SNTISenti Biosciences2.8462 of 5 stars3.55.00.00.01.80.01.3TRDAEntrada Therapeutics2.7356 of 5 stars3.62.00.00.02.41.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNTCBenitec Biopharma 3.22Buy$24.7154.46% UpsideOLMAOlema Pharmaceuticals 3.00Buy$24.50464.52% UpsideSNTISenti Biosciences 3.00Buy$12.00288.35% UpsideTRDAEntrada Therapeutics 3.25Buy$25.67210.36% UpsideCurrent Analyst Ratings BreakdownLatest SNTI, TRDA, OLMA, and BNTC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025TRDAEntrada TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.005/19/2025BNTCBenitec BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.005/15/2025BNTCBenitec BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$20.00 ➝ $20.005/14/2025OLMAOlema PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$20.00 ➝ $18.005/14/2025OLMAOlema PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$25.00 ➝ $22.005/2/2025SNTISenti BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.004/28/2025OLMAOlema PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.004/10/2025BNTCBenitec BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$18.00 ➝ $20.003/31/2025TRDAEntrada TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.003/28/2025OLMAOlema PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$30.00 ➝ $28.003/24/2025BNTCBenitec BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNTCBenitec Biopharma$80K5,120.00N/AN/A$3.24 per share4.94OLMAOlema PharmaceuticalsN/AN/AN/AN/A$4.61 per shareN/ASNTISenti Biosciences$2.56M31.48N/AN/A$15.02 per share0.21TRDAEntrada Therapeutics$172.22M1.82N/AN/A$7.26 per share1.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNTCBenitec Biopharma-$21.75M-$1.51N/AN/AN/AN/A-44.61%-41.25%N/AOLMAOlema Pharmaceuticals-$96.65M-$2.01N/AN/AN/AN/A-53.56%-47.86%8/5/2025 (Estimated)SNTISenti Biosciences-$71.06M-$10.84N/AN/AN/AN/A-154.84%-77.42%8/12/2025 (Estimated)TRDAEntrada Therapeutics-$6.68M$0.815.20N/AN/A25.53%16.11%10.39%8/12/2025 (Estimated)Latest SNTI, TRDA, OLMA, and BNTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q3 2025BNTCBenitec Biopharma-$0.36-$0.24+$0.12-$0.24N/AN/A5/13/2025Q1 2025OLMAOlema Pharmaceuticals-$0.49-$0.36+$0.13-$0.36N/AN/A5/8/2025Q1 2025TRDAEntrada Therapeutics-$0.78-$0.42+$0.36-$0.42$10.98 million$8.75 million5/6/2025Q1 2025SNTISenti Biosciences-$0.56-$1.41-$0.85-$1.41$1.30 million$1.30 million3/20/2025Q4 2024SNTISenti Biosciences-$3.13-$0.67+$2.46-$0.67$2.80 million$5.86 million3/18/2025Q4 2024OLMAOlema Pharmaceuticals-$0.63-$0.51+$0.12-$0.51N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBNTCBenitec BiopharmaN/AN/AN/AN/AN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/AN/ASNTISenti BiosciencesN/AN/AN/AN/AN/ATRDAEntrada TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNTCBenitec BiopharmaN/A25.4815.01OLMAOlema PharmaceuticalsN/A7.107.10SNTISenti BiosciencesN/A1.921.92TRDAEntrada TherapeuticsN/A6.596.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNTCBenitec Biopharma52.19%OLMAOlema Pharmaceuticals91.78%SNTISenti Biosciences25.73%TRDAEntrada Therapeutics86.39%Insider OwnershipCompanyInsider OwnershipBNTCBenitec Biopharma1.30%OLMAOlema Pharmaceuticals19.40%SNTISenti Biosciences3.12%TRDAEntrada Therapeutics8.11%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNTCBenitec Biopharma2025.60 million23.15 millionNo DataOLMAOlema Pharmaceuticals7068.42 million46.18 millionOptionableSNTISenti Biosciences426.08 million4.30 millionNot OptionableTRDAEntrada Therapeutics11037.95 million34.58 millionOptionableSNTI, TRDA, OLMA, and BNTC HeadlinesRecent News About These CompaniesEntrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of DirectorsJune 3 at 7:00 AM | globenewswire.comEntrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 2 at 4:30 PM | globenewswire.comEntrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients ...May 29, 2025 | morningstar.comEntrada Therapeutics to start DMD trial in Q3 2025May 29, 2025 | investing.comEntrada Therapeutics Receives EU Authorization to Proceed with ELEVATE-45-201 Clinical Study for Duchenne Muscular Dystrophy, Set to Begin in Q3 2025May 29, 2025 | nasdaq.comEntrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 SkippingMay 28, 2025 | globenewswire.comQ2 EPS Estimate for Entrada Therapeutics Raised by AnalystMay 24, 2025 | marketbeat.comHC Wainwright Has Positive Forecast for TRDA Q2 EarningsMay 24, 2025 | americanbankingnews.comWhat is HC Wainwright's Estimate for TRDA Q2 Earnings?May 23, 2025 | marketbeat.comNorthern Trust Corp Has $5.50 Million Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)May 23, 2025 | marketbeat.comEntrada Therapeutics (NASDAQ:TRDA) Given "Buy" Rating at HC WainwrightMay 22, 2025 | marketbeat.comJanus Henderson Group PLC Acquires 368,908 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA)May 17, 2025 | marketbeat.comMPM Asset Management LLC Decreases Stock Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)May 16, 2025 | marketbeat.comQ2 EPS Forecast for Entrada Therapeutics Reduced by AnalystMay 16, 2025 | marketbeat.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Purchased by Dimensional Fund Advisors LPMay 16, 2025 | marketbeat.comEntrada Therapeutics (NASDAQ:TRDA) Issues Earnings ResultsMay 12, 2025 | marketbeat.comAnalysts Are Upgrading Entrada Therapeutics, Inc. (NASDAQ:TRDA) After Its Latest ResultsMay 11, 2025 | finance.yahoo.comEntrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue EstimatesMay 8, 2025 | zacks.comEntrada Therapeutics Reports First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comEntrada Trims Workforce by 20 Percent to Focus on Advancing DMD, Other CandidatesMay 2, 2025 | precisionmedicineonline.comEntrada Cuts 20% of Workforce, Targeting Research EmployeesApril 30, 2025 | biospace.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSNTI, TRDA, OLMA, and BNTC Company DescriptionsBenitec Biopharma NASDAQ:BNTC$16.00 +0.39 (+2.50%) As of 01:07 PM EasternBenitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.Olema Pharmaceuticals NASDAQ:OLMA$4.34 -0.04 (-0.91%) As of 01:33 PM EasternOlema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.Senti Biosciences NASDAQ:SNTI$3.09 0.00 (0.00%) As of 01:27 PM EasternSenti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Entrada Therapeutics NASDAQ:TRDA$8.27 +0.13 (+1.60%) As of 01:33 PM EasternEntrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Reasons Amazon Could Be the Best Tech Performer in June Applied Digital: CoreWeave’s AI Deal Lights a $7 Billion Fuse Steel Dynamics Shares Climb After Tariff Announcement Palantir Soars on Government Deals as Valuation Debate Lingers Broadcom Earnings Preview: AVGO Stock Near Record Highs Why Super Micro Computer's Upside Could Trigger a Short Squeeze Zscaler Will Hit $360 Soon: Here’s the How and Why Buy The Dip in Okta, There’s Nothing Wrong With the Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
